Examples of using Are summarized in table in English and their translations into Slovenian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Official/political
-
Programming
These impacts are summarized in Table 1.
Bone Mineral Density(BMD) data from Study GS-US-174-0115 are summarized in Table 8:.
Podatki o mineralni gostoti kosti(MGK) iz študije GS-US-174-0115 so povzeti v preglednici 8:.Given these potential outcomes- which are summarized in table 4.5- one can define the causal effect of the treatment for person\(i\) as.
Glede na te morebitne rezultate, ki so povzeti v tabeli 4.5, lahko določimo vzročni učinek zdravljenja za osebo \(i\) kot.The efficacy results from Study MO16432 are summarized in Table 11.
Rezultati učinkovitosti študije MO16432 so povzeti v preglednici 11.Efficacy results are summarized in Table 5.
Rezultati o učinkovitosti so povzeti v preglednici 5.PCDD/F emission control measures for the metallurgical industries are summarized in table 2.
Ukrepi za nadzor emisijami PCDD/F The study results are summarized in Table 13.
Izsledki študije so povzeti v preglednici 13.Efficacy results from AURA studies as well as pooled analysis(AURAex and AURA2) are summarized in Table 3.
Rezultati učinkovitosti iz študij AURA in združena analiza(AURAex in AURA2) so povzeti v preglednici 3.The study results are summarized in Table 15.
Rezultati študije so povzeti v preglednici 15.The efficacy results from the BO16348 trial following 12 months*and 8 years** median follow-up are summarized in Table 6:.
Rezultati učinkovitosti študije BO16348 po medianem času spremljanja 12mesecev* in 8 let** so povzeti v preglednici 6.Main study results are summarized in Table 5.
Glavni rezultati študije so povzeti v preglednici 5.Highlights of BPA on classification and labelling under the new law and Regulation(EU)758/2013 are summarized in Table 1.
Poudarki BPA za razvrščanje in označevanje The efficacy outcomes are summarized in Table 2.
Rezultati učinkovitosti so zbrani v preglednici 2.The comparison of predicted median Cmax datafor MabThera subcutaneous formulation and intravenous formulation are summarized in Table 7.
Primerjava podatkov za predvideno mediano največje koncentracije(Cmax)za podkožno in intravensko obliko zdravila MabThera je povzeta v preglednici 7.Guidelines for dose modifications are summarized in Table 1.
Smernice za prilagoditev odmerka so povzete v tabeli 1.Children and adolescents: Multiple-dose pharmacokinetic properties for Viraferon injection and ribavirin capsules in children and adolescents with chronic hepatitis C,between 5 and 16 years of age, are summarized in Table 6.
Otroci in mladostniki: Farmakokinetične lastnosti pri dajanju večih odmerkov zdravila Viraferon injekcije in ribavirin kapsule pri otrocih in mladostnikih s kroničnim hepatitisomC Objective response rate findings are summarized in Table 4.
Izsledki stopnje objektivnega odziva so povzete v preglednici 4.Multiple-dose pharmacokinetic properties for IntronA injection and ribavirin capsules in children and adolescents with chronic hepatitis C,between 5 and 16 years of age, are summarized in Table 6.
Farmakokinetične lastnosti pri večkratnem odmerjanju zdravila IntronA injekcije in kapsul ribavirina pri otrocih in mladostnikih s kroničnim hepatitisomC Key results from all four studies are summarized in table 3.
Ključni rezultati iz vseh štirih študij so povzeti v preglednici 3.Highlights of BPA migration under the proposed Directive for toy safety,and its comparison with Directive 2014/81/EU, are summarized in Table 1.
Poudarki migracij BPA Key results from all four studies are summarized in table 4.
Ključni rezultati vseh štirih preskušanj so povzeti v preglednici 4.Very common ADRs from the BR 21 and PA 3 studies are presented in Tables 1 and 3,other ADRs including those from other studies are summarized in Table 4.
Zelo pogosti neželeni učinki iz študij BR.21 in PA.3 Performance standards that can be achieved are summarized in table 1.
Emisijske vrednosti, ki jih je mogoče doseči, povzema Tabela 1.Multiple-dose pharmacokinetic properties for ribavirin and interferon alfa-2b in children and adolescents with chronic hepatitisC between 5 and 16 years of age are summarized in Table 15.
Farmakokinetične lastnosti pri večkratnem odmerjanju ribavirina in interferona alfa-2b pri otrocih in mladostnikih s kroničnim hepatitisomC Rates of subjects with PRNT50≥1:10 and GMTs at Months 2, 6, 12,24 and 36 are summarized in Table 3 for the ITT population.
Odstotki oseb s PRNT50≥1:10 in geometrični srednji titri Recommended modifications for pancreatic adverse reactions are summarized in Table 2.
Priporočeno prilagajanje pri neželenih reakcijah, povezanih s trebušno slinavko, je povzeto v preglednici 2.The pregnancy results from the first two FTET cycles of ENGAGE andPURSUE are summarized in Table 3 below.
Rezultati nosečnosti iz prvih dveh FTET ciklov študij ENGAGE inPURSUE so povzeti v Preglednici 3 spodaj.The pregnancy results from the fresh cycles of ENGAGE and PURSUE are summarized in Table 2 below.
Rezultati nosečnosti iz ciklov z uporabo svežih zarodkov The pharmacokinetic parameters for efavirenz at steady state in paediatric patientswere predicted by a population pharmacokinetic model and are summarized in Table 4 by weight ranges that correspond to the recommended doses.
Farmakokinetični parametri efavirenza 
